Name | Value |
---|---|
Revenues | 0.0K |
Cost of Revenue | 4.0K |
Gross Profit | -4.0K |
Operating Expense | 9,035.0K |
Operating I/L | -9,039.0K |
Other Income/Expense | 97.0K |
Interest Income | 0.0K |
Pretax | -8,942.0K |
Income Tax Expense | 0.0K |
Net Income/Loss | -8,942.0K |
Aileron Therapeutics, Inc. is a clinical stage chemoprotection oncology company focused on developing ALRN-6924, a promising drug candidate currently in various clinical trials for the treatment of solid tumors, lymphoma, peripheral T-cell lymphoma, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS). The company also conducts combination trials of ALRN-6924 with other drugs for enhanced efficacy. Aileron Therapeutics generates revenue through its research and development efforts, as well as through potential future commercialization of ALRN-6924 and any other successful drug candidates in its pipeline.